AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
The phase 3 trials that will decide whether alpha-emitting PSMA drugs become the next step after Pluvicto.
AlphaBreak (FPI-2265, 225Ac-PSMA-I&T, AstraZeneca/Fusion) and Novartis' AcTION programme of 225Ac-PSMA-617 in post-Lu and Lu-naive settings; Bayer's PAnTHA phase 1 of 225Ac-PSMA-Trillium reported at ASCO GU 2026. Xerostomia and Ac-225 supply are the constraints.
Pages like this
not linked directly; found by shared links- PersonClemens Kratochwil
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- InstitutionOslo University Hospital – The Norwegian Radium Hospital
Shares Bayer, Targeted alpha therapy, Prostate cancer.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
- ProductRadium-223 dichloride
Shares Bayer, Targeted alpha therapy, Prostate cancer.
- TrialALSYMPCA
Shares Targeted alpha therapy, Prostate cancer.
- ProductDarolutamide
Shares Bayer, Prostate cancer.